Clinical trials: Risperidone
Oppositional Defiant Disorder, Conduct Disorder
Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone.
This study was developed in order to assess the effects of risperidone (Risperdal) as compared with placebo on cognitive-motor performance (attention, memory, and hand steadiness) and body movements.
- Conditions
- Oppositional Defiant Disorder, Conduct Disorder, Attention Deficit/Hyperactivity Disorder (ADHD), Intermittent Explosive Disorder
- Trial name
- NCT00399698
- Testing
- Risperdal
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ohio State University
Schizophrenia
A Follow-Up Study of Schizophrenic Participants Following Treatment Discontinuation After Remission From a First Psychotic Episode
The purpose of this study is to evaluate the outcome of medication discontinuation, the safety and effectiveness of re-initiating risperidone long acting injection (RLAI) in case of relapse (the return of a medical problem) of…
- Trial name
- NCT00378092
- Testing
- Oral risperidone, Risperidone Long-Acting Injection (RLAI)
- Where
- South Africa
- Volunteers
- 33 people
- Sponsor
- Janssen Cilag N.V./S.A.
Psychotic Disorders
Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics
This study will test the effectiveness of two different treatments for children and adolescents who have gained weight on their antipsychotic medications.
- Trial name
- IMPACT (NCT00806234)
- Testing
- Aripiprazole or Perphenazine, Metformin, Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine
- Where
- 4 sites in United States
- Volunteers
- 127 people
- Sponsor
- Johns Hopkins University
Prodromal Schizophrenia, Psychotic Disorders
Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms
The Recognition and Prevention (RAP) Program is conducting a research study comparing an antidepressant, sertraline, alone versus in combination with a second-generation antipsychotic, risperidone, to evaluate their ability to…
- Trial name
- NCT00169988
- Testing
- risperidone, sertraline-primary
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Northwell Health
Diabetes
Metabolic Effects of Antipsychotic Substitution in Children
This project aims to identify whether therapeutic substitution of aripiprazole for risperidone or olanzapine, combined with standard nutrition intervention, will impact the metabolic changes associated with antipsychotic…
- Trial name
- SMEAC (NCT00910780)
- Testing
- Aripiprazole, Zyprexa, Risperdal
- Sponsor
- Washington University School of Medicine
Schizophrenia, Bipolar Disorder
A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children
The purpose of this study is to evaluate the effects of risperidone compared with other atypical antipsychotic drugs on the physical maturity, growth and development of children, and the risk of prolactin-related adverse events…
- Conditions
- Schizophrenia, Bipolar Disorder, Autistic Disorder, Conduct and Other Disruptive Behavior Disorders
- Trial name
- NCT01050582
- Testing
- Risperidone, Other atypical antipsychotic drugs
- Where
- 28 sites in United States, Belgium and 4 more
- Volunteers
- 244 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Investigate Risperidone for the Treatment of Schizophrenia in Adolescents
A clinical study to evaluate the efficacy, safety and tolerability of two dose ranges of risperidone (1 to 3 mg/day, and 4 to 6 mg/day) versus placebo (an inactive substance like a sugar pill) in adolescents (aged 13 to 17 years)…
- Trial name
- NCT00088075
- Testing
- Risperidone
- Volunteers
- 160 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Psychotic Disorders
Striatal Connectivity and Clinical Outcome in Psychosis
This is an observational neuroimaging treatment study. This study involves examining the neural circuitry of controlled treatment of patients presenting with a first-episode of psychosis with risperidone or aripiprazole.
- Trial name
- NCT02822092
- Testing
- Risperidone or Aripiprazole (patients only)
- Where
- United States
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Dissociative Disorders, Schizophrenia
Assessment of Adverse Events in a Naive Pediatric Population Treated With an Antipsychotic
We propose a prospective multicenter study, whose originality lies in the inclusion of the naive child and adolescent population.
- Trial name
- NCT02007928
- Testing
- Rispéridone, aripiprazole, olanzapine
- Where
- 14 sites in France
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Child Development Disorders, Pervasive
RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders
This 24-week study will compare the safety and effectiveness of medication treatment alone (risperidone or aripiprazole) to medication treatment in combination with a parent management training program.
- Trial name
- NCT00080145
- Testing
- Risperidone, Behavior Therapy
- Where
- 3 sites in United States
- Volunteers
- 124 people
- Sponsor
- Yale University
Attention Deficit Disorder With Hyperactivity
Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study)
This study will determine the advantages and disadvantages of adding one of two different types of drugs to stimulant treatment for reducing aggressive behavior in children with attention deficit with hyperactivity disorder…
- Trial name
- NCT00794625
- Testing
- Valproate, Risperidone, Stimulant medication
- Where
- 3 sites in United States
- Volunteers
- 270 people
- Sponsor
- Joseph Blader
Schizophrenia, Treatment-resistant Schizophrenia
Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis
SchizOMICS is a Phase IV, multicenter, dose-flexible, open-label, randomized controlled clinical trial to evaluate the efficacy and safety of aripiprazole versus paliperidone using multi-omics data in patients with a first…
- Conditions
- Schizophrenia, Treatment-resistant Schizophrenia, Side Effect, Lipid Metabolism Disorders
- Trial name
- SchizOMICS (NCT06060886)
- Testing
- Aripiprazole, Paliperidone
- Volunteers
- 244 people
- Sponsor
- Consorcio Centro de Investigación Biomédica en Red (CIBER)
Risperidone-induced Hyperprolactinemia
Calcium and Vitamin D to Optimize Bone Mass in Boys With Risperidone-induced Hyperprolactinemia
The purpose of this study is to determine whether calcium and vitamin D supplementation, over a nine-month period, optimizes bone mineralization in boys with risperidone-induced hyperprolactinemia.
- Trial name
- NCT00799383
- Testing
- Calcium and Vitamin D
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Chadi A. Calarge
Schizophrenia, Mental Illness
A Research in Pharmacogenomics and Accurate Medication of Risperidone
Risperidone is a selective monoamine receptor antagonist. It plays an antipsychotic effect by antagonizing 5-HT2 / D2 receptor. As a second-generation antipsychotic drug, risperidone is metabolized to 9-hydroxy Risperidone in the…
- Trial name
- NCT03302364
- Testing
- Risperidone
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Cui Yimin
Autism
Pharmacogenomics in Autism Treatment
Autism is a complex neurodevelopmental disorder that is thought to involve an interaction between multiple and variable susceptibility genes, environmental factors, and epigenetic effects.
- Trial name
- PG (NCT00584701)
- Testing
- Risperidone
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- University of California, San Francisco
Schizophrenia
Guideline vs Usual Treatment in Schizophrenic Adolescents
The purpose of this study was to evaluate the applicability and usefulness of the guideline treatment for diagnosis and treatment of adolescents with schizophrenia, also to evaluate the compliance to the treatment according to…
- Trial name
- ACER (NCT02573701)
- Testing
- Guideline treatment (Risperidone, administered orally), "Psychosocial treatment", Treatment as Usual (any other antipsychotic)
- Volunteers
- 91 people
- Sponsor
- Hospital Psiquiatrico Infantil Dr. Juan N. Navarro, Mexico
Schizophrenia, Mental Disorders
Study of the Activation of Proinflammatory Pathways of Toll-like Receptors in Schizophrenia Patients
The study of immune pathways involved in the etiopathogeny of schizophrenia would be an important advance to understand the mechanisms involved in the development of this disease and it would be a turning point in drug therapy.
- Conditions
- Schizophrenia, Mental Disorders, Psychotic Disorders
- Trial name
- PAFIP_TLR (NCT02897167)
- Testing
- Retrospective study of frozen samples, Prospective study of fresh samples
- Where
- Spain
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Attention Deficit/Hyperactivity Disorder, Oppositional Defiant Disorder
Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders
Attention Deficit/Hyperactivity Disorder (ADHD) is one the most prevalent mental disorders among children and adolescents, with a prevalence of 5% in western culture.
- Conditions
- Attention Deficit/Hyperactivity Disorder, Oppositional Defiant Disorder, Conduct Disorder
- Trial name
- NCT02063945
- Testing
- Methylphenidate, Risperidone
- Where
- Israel
- Volunteers
- 5 people
- Sponsor
- Sheba Medical Center
Schizophrenia
Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis
This 52 week long study evaluates the effectiveness of aripiprazole versus risperidone in treating people with first-episode schizophrenia.
- Trial name
- NCT00320671
- Testing
- Aripiprazole, Risperidone
- Where
- United States
- Volunteers
- 198 people
- Sponsor
- Northwell Health
Bipolar Disorder
Controlled Trial of Valproate Versus Risperidone in Young Children With Bipolar Disorder
Controlled trial of the efficacy and safety of valproate, versus risperidone in children, ages 3-7 yr. with Bipolar I or II Disorder, mixed, manic or hypomanic episode.
- Trial name
- NCT02456454
- Testing
- Risperidone, Valproic Acid
- Volunteers
- 46 people
- Sponsor
- Nationwide Children's Hospital